Morgan Stanley Raises Price Target on Check Point Software Technologies to $170 From $155, Keeps Equalweight Rating
CyberArk Software Analyst Ratings
Barclays Remains a Buy on CyberArk Software (CYBR)
Teva Pharmaceutical Indus Analyst Ratings
Argus Upgrades Teva to Buy, Cites Recent Drug Approvals
NICE Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
CyberArk Software Analyst Ratings
CyberArk Software Analyst Ratings
CyberArk Software Analyst Ratings
Wedbush Reiterates Outperform on NICE, Maintains $250 Price Target
NICE Analyst Ratings
RBC Capital Cuts Price Target on NICE to $230 From $265, Maintains Outperform Rating
Wix.com Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
CyberArk Software Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Wix.com Analyst Ratings
CyberArk Software Analyst Ratings
CyberArk Software Analyst Ratings